التكنولوجيا وأخبارها بوابة الإمارات لتكنولوجيا المعلومات والإتصالات
• Reported revenues of €2.2 billion represent an increase of €417 million (23.2%) on 2018
• Operating income of €424 million represents an increase of €78.6 million (22.7%) on 2018
• All products performed well, but highlights are the year-on-year growth of the Group’s immunoglobulin product portfolio, as well as Nuwiq®, albunorm® and fibryga®
Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019.
We achieved good growth in all three of our therapeutic areas. We continued to invest significantly in R&D to fund the discovery and development of new life-changing treatments,
as well as in our plasma collection capacities to ensure the future supplies of our life-saving products for patient
s. Our new subcutaneous immunoglobulin (SCIG), cutaquig®,
received approval in Europe following approvals in 2018 in the USA and Canada.
The European Medicines Agency (EMA) approved an updated label for our recombinant factor VIII (rFVIII), Nuwiq® to include data on effective bleed protection with twice
weekly dosing using personalised prophylaxis.
Fibryga® received European approval to treat acquired fibrinogen deficiencies,
extending the earlier approval for use in patients with congenital fibrinogen deficiency.
These approvals bring substantial benefits to patients as well as physicians. Based on our existing product portfolio and our development pipeline, Octapharma is well positioned to
continue to perform strongly in the coming years.”
The Octapharma Group has delivered a strong performance in 2019.
Sales of €2.2 billion represent an increase of €417 million (23.2%) compared to 2018. Furthermore, operating income increased by €78.6 million (22.7%) compared with 2018, to €424 million.
Gross profit in 2019 was €783 million, which is €152 million more than 2018. Despite continued investments in plasma collection and production capacities to fulfil the growing
global demand for our products,
gross margin increased by 0.3% to 35.4%.
Significant investments were made for the Group’s future prosperity in R&D and into the extension of plasma collection and production capacities.
Important milestones in the expansion and utilisation of the plasma and recombinant product portfolio became a reality during the last 12 months.
To ensure each litre of plasma is optimally used,
the Group will continue to enter new markets and expand its portfolio with innovative new products and services.
“Last year our products touched hundreds of thousands of patients globally,” said Roger Mächler,
Chief Financial Officer of the Octapharma Group.
“Our significant investments in research and infrastructure strongly position Octapharma to fulfil the unmet needs of more healthcare professionals and patients around the world in the coming years.”
The Annual Report 2019 provides a comprehensive overview of the Octapharma Group, including details of corporate governance and the financial results.
